FDA Approval for Axi-Cel in NHL – OncLive
OncLive |
FDA Approval for Axi-Cel in NHL
OncLive David Maloney, MD, PhD: We’re tremendously excited to have an approved CAR T-cell for lymphoma. And axi-cel, or axicabtagene ciloleucel, was the first one. The results for the study were basically treating 101 patients with a CAR and they had to have … |
|
This Week in Science
GenomeWeb Also in Science, researchers from MIT’s Synthetic Biology Center discuss the potential of gene programming and genetically engineered cellular therapy, as well as the limitations facing their clinical implementation. Despite some success in treating … |